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Abstract
Neuroblastomas (NBs) are a clinically heterogeneous group of extra cranial pediatric tumors. Patients with high-risk,
metastatic NBs have a long-term survival rate of below 40%, and are often resistant to current therapeutic modalities. Due
to toxic side effects associated with radiation and chemotherapies, development of new agents is warranted to overcome
resistance and effectively treat this disease in clinic. CARP-1 functional mimetics (CFMs) are an emerging class of small
molecule compounds that inhibit growth of diverse cancer cell types. Here we investigated NB inhibitory potential of CFMs
and the molecular mechanisms involved. CFM-1, -4, and -5 inhibited NB cell growth, in vitro, independent of their p53 and
MYCN status. CFM-4 and -5 induced apoptosis in NB cells in part by activating pro-apoptotic stress-activated kinases (SAPKs)
p38 and JNK, stimulating CARP-1 expression and cleavage of PARP1, while promoting loss of the oncogenes C and N-myc as
well as mitotic cyclin B1. Treatments of NB cells with CFM-4 or -5 also resulted in loss of Inhibitory kB (IkB) a and b proteins.
Micro-RNA profiling revealed upregulation of XIAP-targeting miR513a-3p in CFM-4-treated NB, mesothelioma, and breast
cancer cells. Moreover, exposure of NB and breast cancer cells to CFM-4 or -5 resulted in diminished expression of anti-
apoptotic XIAP1, cIAP1, and Survivin proteins. Expression of anti-miR513a-5p or miR513a-5p mimic, however, interfered
with or enhanced, respectively, the breast cancer cell growth inhibition by CFM-4. CFMs also impacted biological properties
of the NB cells by blocking their abilities to migrate, form colonies in suspension, and invade through the matrix-coated
membranes. Our studies indicate anti-NB properties of CFM-4 and 5, and suggest that these CFMs and/or their future
analogs have potential as anti-NB agents.
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Introduction
Neuroblastoma (NB) is the most common malignant extra
cranial solid tumor of children, and account for 8–10% of
pediatric cancers [1]. Higher stage of disease, age of .18 months,
MYCN amplification, and unfavorable histology are indicators of
poor prognosis [1,2]. The current treatment regimens include
high-dose chemotherapy with autologous stem cell transplanta-
tion, radiation and surgery. In the high-risk metastatic NBs, the
long-term survival rates are ,40% [3,4]. However, NB frequently
relapses with resistant disease due in part to selection of drug-
resistant cells during treatment [5]. Therefore, new therapeutic
strategies are needed to overcome drug resistance and improve
anti-neuroblastoma treatment outcomes.
Cell cycle and apoptosis regulator 1 (CCAR1/CARP-1) is a
peri-nuclear phospho-protein, that regulates cell growth and
apoptosis signaling in a variety of cancer cells [6–8]. CARP-1
functions as a key transcriptional co-activator of steroid family of
nuclear receptors and tumor suppressor p53 in regulating
Adriamycin (ADR)-dependent DNA damage-induced apoptosis.
Increased CARP-1 expression also occurs during cell cycle arrest
and apoptosis following withdrawal of the serum growth factors
[6–8]. Recent studies revealed that CARP-1 phosphorylation plays
a significant role in mediating apoptosis. For example, apoptosis
stimulation following blockage of EGFRs involves CARP-1
phosphorylation at tyrosine192, activation of p38 MAPK and
caspase-9. Pharmacologic inhibition of protein kinase A (PKA)
results in CARP-1 threonine667 phosphorylation, abrogation of c-
Myc transcription and inhibition of human breast cancer cell
growth [8,9]. Depletion of CARP-1, on the other hand, resulted in
resistance to apoptosis with ADR or EGFR tyrosine kinase
inhibitors [6].
Our recent studies demonstrated that CARP-1 also functions as
a co-activator of cell cycle regulatory anaphase promoting
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complex/cyclosome (APC/C) E3 ligase [10]. APC/C is a multi-
subunit ubiquitin E3 ligase protein that plays a distinct role in cell
cycle transitions [11,12]. Previous studies showed that misregula-
tion of APC/C and its substrates correlates with tumor progression
[13]. We identified a novel class of small molecule inhibitors
(SMIs) of CARP-1 binding with APC/C subunit APC2. These
compounds, termed CARP-1 functional mimetics (CFMs), inhibit
cell growth by inducing apoptosis in various cancer types
[10,14,15]. Here we provide evidence that CFMs are novel and
potent inhibitors of NB cell growth.
Materials and Methods
Cells and reagents
Four human NB cell lines (SK-N-AS, SK-N-DZ, SK-N-BE(2),
and SK-N-SH) were purchased from ATCC, and were kindly
provided by Dr. Yubin Ge, Karmanos Cancer Institute, Wayne
State University, Detroit, MI. The NB cells were routinely
cultured either in the RPMI-1640 (SK-N-BE(2) and SK-N-SH)
or in DMEM (SK-N-AS, SK-N-DZ) medium that was supple-
mented with 10% FBS, 100 units/ml of penicillin, and 100 mg/ml
of streptomycin. Cells were maintained at 37uC and 5% CO2 [16].
Human breast cancer (HBC) MDA-MB-468 and MDA-MB-231
cells (that lack estrogen receptor and have mutant p53) were also
purchased from ATCC, and routinely cultured in our laboratory
essentially as described [6]. MDA-MB-468 subline (AS clone 9)
expressing reduced CARP-1 following stable expression of CARP-
1 antisense were generated and characterized as detailed before
[6], while malignant pleural mesothelioma (MPM) H2373 cells
were cultured as described previously [14].
DMEM, RPMI-1640 medium, penicillin and streptomycin
were purchased from Invitrogen Co. (Carlsbad, CA). CFM-1, -4
and -5 were obtained from ChemDiv, San Diego, and Ryan
Scientific, Inc., Mt. Pleasant, SC, and were dissolved in dimethyl
sulfoxide (DMSO) at a stock concentration of 10, 50, and 50 mM,
respectively, and stored at 220uC. FBS was purchased from
Denville Scientific Inc. (Metuchen, NJ), and DMSO was
purchased from Fischer Scientific (Fair Lawn, NJ). Anti-b-actin
mouse monoclonal antibody, and 3-4, 5-dimethyltiazol-2-yl-2.5-
diphenyl-tetrazolium bromide (MTT) were purchased from
Sigma-Aldrich (St. Louis, MO). The monoclonal antibodies for
ABIN2, the polyclonal antibodies for TIMP2 (goat polyclonal),
DR4 and DR5 were obtained from Santa Cruz Biotech, Santa
Cruz, CA. The mouse monoclonal antibody for a-tubulin was
obtained from Calbiochem (Billerica, MA). Anti-cyclin B1, anti
phospho-JNK (Threonine183/Tyrosine185) G9 mouse monoclo-
nal antibodies, anti-JNK (56G8), anti-XIAP (3B6), anti-Survivin
(71G4B7) rabbit monoclonal antibodies, and rabbit polyclonal
antibodies for PARP, phospho and total p38a/b SAPK, ABIN1,
IkBa, IkBb, and c-IAP1 were obtained from Cell Signaling
Technology (Beverly, MA). Rabbit polyclonal antibody for
MYCN was obtained from Abcam (Cambridge, MA). Generation
and characterization of the anti-CARP-1/CCAR1 rabbit poly-
clonal antibodies have been described elsewhere [6]. Enhanced
Chemiluminescence Reagent was purchased from Amersham
Biosciences (Piscataway, NJ) and the Protein Assay Kit was
purchased from Bio-Rad Laboratories (Hercules, CA). The NF-
kB-TATA-Luc plasmid that contains 5x NF-kB consensus cis
sequences/enhancer positioned upstream of the TATA elements
that drive firefly luciferase reporter expression, and the plasmid for
expression of Renilla luciferase (pTK/Renilla Luc used as internal
control for transfections) were purchased from Stratagene, Inc.
(LaJolla, CA) and Promega, Inc (Madison, WI), respectively.
Cell cycle analysis, MTT, apoptosis and Western blot
assays
The cell cycle distribution was analyzed by flow cytometry. NB
cells (16106) were untreated or treated with respective CFM, and
harvested and washed in PBS. The cells were then fixed in 70%
alcohol for 30 min at 4uC. The cells were subsequently washed
thrice in cold PBS, and suspended in 1 ml of PBS containing
50 mg of propidium iodide and 100 mg of RNAseA for 30 min at
37uC. The cells were then analyzed for their DNA content by
FACSCalibur (Becton-Dickinson, Mountain View, CA).
In vitro inhibition of cell growth was assessed by MTT (3-[4, 5-
dimethyltiazol-2-yl]-2.5-diphenyl tetrazolium bromide) reagent.
Cells (56103) were seeded in a 96-well culture plate and
subsequently treated with respective CFMs and Adriamycin
(ADR) at different concentrations as mentioned. Control cells
were treated with 0.1% DMSO in culture medium. After
treatment, the cells were incubated with 1 mg/ml of MTT
reagent at 37uC for 2–4 hours and then MTT was removed and
50 mL of DMSO was added, followed by colorimetric analysis
using a multi-label plate reader at 560 nm (Victor3; PerkinElmer,
Wellesley, MA, USA).
Apoptosis levels were determined by staining for fragmented
DNA utilizing terminal deoxynucleotidyl transferase-mediated
nick end labeling (TUNEL) assay. TUNEL kits were purchased
from Roche Diagnostics, (Indianapolis, IN). For TUNEL labeling,
the cells were either untreated or treated with 5 or 10 mM of
CFM-1, -4, -5 for 12 h. The slides were rinsed to remove the
media, and the cells were fixed for staining using a 1:250 dilution
of anti-CARP-1 (a2), anti-PARP1, anti-MYCN or anti-c-Myc
antibodies, or 1:500 dilution of the anti-phospho-p38 antibody
respectively. The fixed and labeled cells were photographed
essentially as detailed in our previously described methods [17].
For protein expression analysis, Western blot (WB) experiments
were done according to the standard procedures. The cells were
either untreated or treated with CFMs and ADR, harvested and
lysed in cell lysis (10X) buffer (#9803; cell signaling) containing
0.1% of protease and phosphatase inhibitor cocktail (Sigma) for
20 min at 4uC. The lysates were centrifuged at 14,000 rpm at 4uC
for 15–20 min to remove debris. Protein concentrations of whole
cell lysates were determined using the Protein Assay Kit.
Supernatant proteins, 50–100 mg from each sample, were
separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride (PVDF)
membrane (Bio-rad, Hercules, CA) by standard procedures. The
membranes were hybridized with primary antibodies followed by
incubation with appropriate secondary antibodies. The antibody-
bound proteins were visualized by treatment with the chemilumi-
nescence detection reagent according to manufacturer’s instruc-
tions, followed by exposure to X-ray film (Denville Scientific Inc.).
The same membranes were re-probed with the anti-b-actin or
anti-a-tubulin antibody, which was used as an internal control for
protein loading.
Luciferase assays
Cells were plated either in a 12-well plate or in a 24-well plate at
a density of 36105 cells/ml and then transfected with pTK/
Renilla Luc in combination with NF-kB-TATA-Luc essentially
following previously detailed methods [6,8]. After 5 h incubation
with plasmid DNAs, FBS was added to the transfection media and
cells were allowed to grow for at least 18 h. Cells were left
untreated or treated with TNFa, ADR, or CFM-4. The cells were
then harvested, lysed, and Renilla and firefly luciferase activities
were measured using dual luciferase assay kit (Promega) essentially
following vendors’ guidelines.
CFMs Are Novel Inhibitors of Neuroblastoma
PLOS ONE | www.plosone.org 2 July 2014 | Volume 9 | Issue 7 | e102567
Cell migration, invasion and Clonogenic assays
The NB cells migration in the presence of CFMs was measured
by the ‘‘scratch/wound healing’’ assay. Cells were seeded in a 6-
well plate (,10,000 cells/well), and when attached, a scratch was
created in the cell monolayer using sterile pipette tip. The cells
were then allowed to continue growing in the absence (Control) or
presence of 3 mM dose of each of the CFMs for additional 72–
96 h. The cells were photographed at the beginning and at regular
intervals during the treatment period, and the images from control
cells were compared with the treated cells to determine the
migration of the cells essentially as described before [18]. The
photomicrographs of the cells were recorded under different
magnifications utilizing Zeiss microscope with attached 35 mm
camera.
Invasion assay. An in vitro assay using matrigel was utilized
for invasion assay. Since the metastatic tumor cells often produce
proteases that degrade the extracellular matrix (ECM) to facilitate
their migration through stroma, the in vitro assay using Matrigel is
considered to be the most reliable, reproducible, and representa-
tive of in vivo invasion by the cancer cells. In this assay, cancer
cells are placed in the upper chamber that is separated from the
lower chamber by a porous membrane coated with Matrigel
[17,19]. A cell invasion Boyden chamber assay kit (Chemicon
International, CA) was utilized to measure invasion properties of
the NB cells in the absence or presence of CFMs. Briefly, 300 ml of
pre-warmed serum free medium was used to hydrate the ECM
layer of each chamber for 15–30 minutes at room temperature.
Approximately 2–2.56105 NB cells were then seeded in the upper
chamber in a serum-free medium without or with respective
CFMs. Since 10 mM dose of CFMs elicited extensive cell death in
NB cells, a slightly lower dose of 7 mM for each CFM was utilized
over a 24 h treatment period for these assays. The lower chamber
was supplied with medium containing 10% FBS that served as
chemo-attractant to stimulate migration. After an interval, tumor
cells present on the lower side of the membrane in the lower
chamber were stained, and photographed as above. In addition,
the stained cells from the lower side of membrane of some wells
were dissociated, lysed in a buffer, followed by quantitation using a
fluorescence plate reader with 480/520 nm filter set. The
measurements were then plotted as columns in histogram.
Clonogenic assay. A soft-agar sandwitch assay was per-
formed. Cells were sandwiched between 0.6% and 0.3% agarose
in DMEM medium containing 5% FBS in a six-well chamber (500
cells/chamber), and treated with buffer (Control), or respective
CFM (10 mM) for 9 days at 37uC humidified CO2 incubator. The
colonies from multiple random fields were counted, compared to
control and photographed essentially as described before
[14,15,17].
Detection of MMP & TIMP expression in NB cells
SK-N-SH cells were either untreated, separately treated with
CFM-4 or CFM-5. After treatment, the cells were homogenized in
RIPA buffer (500 ml of lysis buffer per 16106 cells), followed by
centrifugation of lysates at 10,0006g for 5 min. The protein
concentration in the respective supernatant was determined by
using Bicinchoninic acid assay, and the lysates were stored at -
80uC until further use. MMP and TIMP activation in each lysate
was measured using the Quantibody reverse phase human MMP
array kit according to manufacturer’s instructions (RayBiotech,
Norcross, GA). Fluorescence images were detected using a
GenePix 4100A Scanner, and data was analyzed using the
QAH-MMP-1 GAL software based on the instruction provided by
the array manufacturer.
MiRNA profiling
The SK-N-SH NB and H2373 MPM cells were either
untreated or treated with 20 mM dose of CFM-4 for 3, 6, 12,
and 24 h periods in serum-free medium. In addition, MDA-MB-
468 HBC cells were separately treated with 20 mM dose of CFM-4
for 1, 6, and 12 h periods in a serum-free medium. At the end of
treatments, the untreated and treated cells were harvested in 1 ml
of Trizol reagent (InVitrogen) and total RNAs were extracted
according to the manufacturer’s protocols. Determination of RNA
quality, labelling, hybridization with miRNA arrays, scanning and
image analysis, and data analysis were custom performed by
Exiqon Inc., Denmark. Briefly, the quality of the RNAs was first
verified by an Agilent 2100 Bioanalyzer profile, and 750 ng of
each of the RNA was labeled with Hy3 and Hy5 fluorescent label,
respectively, using the miRCURY LNA microRNA Hi-Power
Labeling Kit (Hy3/Hy5; Exiqon, Denmark) following the proce-
dure described by the manufacturer. The Hy3-labeled samples
and a Hy5-labeled reference RNA sample were then mixed pair-
wise and hybridized to the miRCURY LNA microRNA Array 7th
gen (Exiqon, Denmark), which contains capture probes targeting
all microRNAs for human, mouse or rat that are currently
registered in the miRBASE 18.0. The hybridization was
performed utilizing a Tecan HS4800 hybridization station (Tecan,
Austria). After hybridization the microarray slides were scanned
and stored in an ozone free environment (ozone level below 2.0
ppb) in order to prevent potential bleaching of the fluorescent
dyes. The miRCURY LNA microRNA Array slides were scanned
using the Agilent G2565BA Microarray Scanner System (Agilent
Technologies, Inc., USA) and the image analysis was carried out
using the ImaGene 9.0 software (BioDiscovery, Inc., USA). The
quantified signals were background corrected (Normexp with
offset value 10) as described [20], and normalized using quantile
normalization method to minimize the intensity-dependent
differences between the samples. The differentially expressed
miRNAs with absolute value of log fold change larger than 1
compared to control were selected for further analysis and
validation.
Anti-miR-513a-5p and miR-513a-5p mimic transfection
Anti-miR-513a-5p, miR-513a-5p mimics and negative control
were purchased from Bioneer (Alameda, CA). 50 nM of Anti-
miR-513a-5p, miR-513a-5p mimic or scrambled negative control
were transfected using Lipofectamine RNAiMAX (Invitrogen) in
serum free medium following manufacturer’s instructions. After
96 h incubation with miRs, the cells were either lysed, and protein
extracts were analyzed by WB for expression of miR-513a-5p
target XIAP protein, or cells were treated with CFM-4 and their
viabilities were determined by MTT assay as above.
Statistical analysis
In some instances, statistical analysis was performed using
unpaired Student’s t-test. A p-value less than 0.05 between
treatment groups was considered significantly different.
Results
NB cell growth suppression by CFMs involves stimulation
of apoptosis
Our previous studies have indicated cancer cell growth
inhibitory properties of CFMs in particular CFM-4 and CFM-5
[10]. In this study, we utilized a number of NB cells (SK-N-SH,
SK-N-BE(2), SK-N-AS, SK-N-DZ) to investigate their growth
inhibition by CFMs. In the first instance, we treated the NB cells
with 5, 10, or 20 mM doses of each CFM or 1, 2, or 5 mg/ml dose
CFMs Are Novel Inhibitors of Neuroblastoma
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of ADR for a period of 12 h. As shown in figure 1A, CFM-4 and -
5 inhibited viability of all the four cell lines in a dose dependent
manner. All the NB cells were inhibited to similar degree by
different doses of ADR with the exception of the SK-N-DZ cells
that were relatively less sensitive to inhibition by ADR. The
growth of the NB cells, with the exception of SK-N-BE(2) cells,
was not affected by treatments with CFM-1 (Figure 1A). SK-N-SH
and SK-N-AS cells harbor single copy of MYCN and WT p53;
while the SK-N-BE(2) have MYCN amplification and mutated
p53 [21–23]. Attenuation of different NB cell growth by CFM-4,
CFM-5, or ADR would suggest for their growth suppression
independent of the involvement of MYCN and/or p53 signaling.
Although ADR is currently utilized in clinic to treat NB, and the
tumors initially respond to ADR therapy, the emergence of ADR
resistance remains a significant and unresolved concern [21].
Since ADR inhibited growth of SK-N-BE(2) cells while SK-N-SH
cells were either unaffected or moderately affected by ADR
treatments, we selected SK-N-SH and SK-N-BE(2) in a proof-of-
concept study to further test the efficacy of CFM-4 and CFM-5
compounds. Both the NB cells were separately treated with
different doses of CFMs or ADR as in figure 1A except that the
treatment period was extended to 24 h. A 20 mM dose of CFM-1
as well as 1 mg/ml dose of ADR caused ,30–33%loss of viability
of both the NB cell lines (Figure 1B, C). The 20 mM dose of CFM-
4 or CFM-5 over a 24 h treatment period induced ,70–80% loss
of viability of both the NB cells (Figure1B, C). Treatments of both
the NB cells with 10 or 20 mM dose of either CFM-4 or CFM-5
elicited consistently and significantly higher loss of cell viabilities
when compared with all the doses of ADR tested (Figure 1B, C).
Since a 5 mg/ml concentration of ADR corresponds to <9.2 mM
dose, and the data in figures 1B and C show a greater inhibition of
the NB cell growth by 10 mM dose of each of the CFM-4 or CFM-
5, it is likely that either of the CFM is superior inhibitor of the NB
growth in comparison with ADR. Because CFM-4 and CFM-5
bind with CARP-1 and interfere with APC/C E3 ubiquitin ligase
functions to regulate cell cycle [10], we determined whether these
compounds interfere with NB cell cycle progression. Flow
cytometric analysis revealed that, like the HBC cells, both the
CFMs caused accumulation of NB cells in G2M phase (Figure 1D).
An MTT-based analysis of the NB and HBC cells treated with
5 mM dose of CFM-4 or CFM-5 over a period of 48 h further
revealed a moderate to minimal loss of viability of the HBC cells
while CFM-4 or CFM-5 treatments resulted in ,70–80%
reduction of NB cells viabilities (Figure 1E). Collectively, the data
in figure 1 suggest that CFM-4 and CFM-5 are effective and
superior inhibitors of NB cell growth, and NB cells are highly
sensitive to inhibition by CFM-4 or CFM-5 when compared with
the HBC cells.
We next determined whether CFMs promoted apoptosis to
inhibit NB cell growth. Based on our MTT analysis, where
treatments with 10 or 20 mM doses of CFM-4 or -5 elicited
significant ,50–80% loss of viability over a period of 24 h in both
the NB cells, while CFM-1 was found to be modestly active, we
chose to utilize 10 and 20 mM doses of CFM-4 and CFM-5 for
Figure 1. CFMs reduce viabilities of the NB cells. Cells were treated with vehicle (Untreated Control), indicated doses of ADR, CFM-1, CFM-4, or
CFM-5, 12 h (A) or 24 h (B, C, E). Determination of viable/live cells was carried out by MTT assay. In panel D, NB cells were treated with indicated dose
and time of CFM-4 or CFM-5, labeled with propidium iodide, and sorted by flow cytometry. The table represents % cell numbers in respective cell
cycle phase. The data in the histograms represent means of three independent experiments; bars, S.E. @, #, * and &, p =,0.05 relative to respective
untreated Controls.
doi:10.1371/journal.pone.0102567.g001
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further experiments to explore the molecular mechanisms of cell
growth suppression and apoptosis stimulation. For determination
of apoptosis, we performed DNA fragmentation-based TUNEL
assay as detailed in methods. Treatments of SK-N-SH or SK-N-
BE(2) NB cells with CFMs resulted in increased number of
TUNEL-positive cells (Figure 2A, B). Further, WB analysis also
revealed increased expression of cleaved PARP-1 (poly(ADP-
ribose) polymerase-1), a marker of apoptosis, following 12 h
treatment of NB cells with the 10 and 20 mM dose of CFM-4 or
CFM-5 (Figure 2C, D). Consistent with earlier findings that
demonstrated involvement of PARP-1 cleavage during ADR-
induced apoptosis [24], treatment of NB cells with 1 and 2 mg/ml
doses of ADR for 12 h also resulted in cleavage of PARP-1. These
data suggest that CFMs, particularly CFM-4 and CFM-5, inhibit
NB cell growth in part by inducing apoptosis.
CFMs promote apoptosis in NB cells by inducing
phosphorylation of p38 MAP kinase, c-Jun N-terminal
kinase (JNK) and stimulating expression of
CCAR-1/CARP-1
CARP-1 has previously been shown to function as a co-activator
of p53 tumor suppressor functions following treatments of cells
with ADR [6,7]. Moreover, knock-down of CARP-1 resulted in
elevated levels of topoisomerase IIa [6] and also interfered with
HBC cell growth inhibition by CFM-4 [10]. To determine
whether NB cell growth suppression and apoptosis induction
involved CARP-1 expression, we first analyzed CARP-1 levels in
NB cells that were treated with CFM-4 or CFM-5 by performing
immuno-cytochemical staining as noted in methods. As shown in
figure 3A, B, immuno-cytochemical analysis revealed elevated
CARP-1 levels in CFM-treated NB cells. Additional WB analysis
of the NB cells that were treated with different doses of CFM-4,
CFM-5, or ADR, showed increased CARP-1 levels when
Figure 2. CFMs induce apoptosis in NB cells. (A, B) Indicated NB cells were either untreated (Control) or treated with 10 mM dose of respective
CFMs for 12 h. Staining of the cells was performed using TUNEL assay as detailed in Methods. Dark brown staining represents fragmented cell nuclei.
(C, D) Cells were either untreated (Control) or treated with indicated agents for noted time and dose, and levels of cleaved PARP and actin proteins
were determined by Western blotting.
doi:10.1371/journal.pone.0102567.g002
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compared with CARP-1 levels in their respective, untreated
controls (Figure 3C, D).
A number of earlier reports have demonstrated activation of
p38 and/or JNK SAPKs in transducing apoptosis signaling in NB
cells [24,25]. To determine the extent SAPKs are also activated by
CFMs, we conducted immuno-cytochemical staining of the CFM-
treated and untreated NB cells for presence of phosphorylated
(activated) p38a/b. As shown in figure 4A, B, treatments with
CFMs resulted in elevated staining for phosphorylated p38a/b.
Further WB analyses revealed increased phosphorylation of p38a/
b as well as JNK1/2 in the CFM-4 or CFM-5-treated NB cells in a
time dependent manner (Figure 4C–F). These data suggest that
NB cell growth inhibition by CFMs involves activation of SAPKs,
and are in agreement with our previous studies demonstrating
stimulation of CARP-1 and activation of SAPKs by CFMs in
HBC, medulloblastoma (MB) and MPM cells [14,15].
CFMs suppress MYCN and c-Myc expression while
activating NF-kB signaling
MYCN amplification plays a significant role in development of
NB and is considered to be a key therapeutic target for NB [26].
We asked whether CFMs target MYCN in NB cells. Immuno-
cytochemical analysis revealed that treatment of SK-N-SH and
SK-N-BE(2) cells with 5 or 10 mM dose of respective CFMs
resulted in diminished staining for MYCN (Figure 5A, B). The
decline in MYCN levels in CFM-treated NB cells was further
confirmed by WB analysis. Both the CFMs caused a noticeable
decline in MYCN levels in SK-N-BE(2) cells (Figure 5C), a more
pronounced loss of MYCN was however noticed in CFM-treated
SK-N-SH cells (Figure 5D). Of note here is that ADR treatments
failed to provoke any loss of MYCN in either of the NB cells
(Figure 5C, D). Our previous studies noted that while stimulating
CARP-1 expression and activation of SAPKs, CFM-4 also caused
loss of mitotic cell cycle regulator cyclin-B1, cell growth and
migration regulatory small GTP-binding protein p21Rac1, and
oncogene c-Myc [10]. Consistent with these observations, our
current immunocytochemical analysis show reduced levels of c-
Myc in CFM-5-treated cells albeit a moderate loss of c-Myc
staining was also noted in SK-N-SH cells that were treated with
CFM-1 or CFM-4 (Figure 5E). WB analysis further show that
although a 10 mM dose of CFM-4 or CFM-5 elicited a moderate
loss of c-Myc expression, exposure of SK-N-SH NB cells to ADR
Figure 3. CFMs upregulate pro-apoptotic CARP-1 levels. (A, B) Indicated NB cells were either untreated (Control), treated with respective CFMs
as in figure 2. Staining of the cells was performed using anti-CARP-1 (a2) antibody as detailed in Methods. Presence of CARP-1 is indicated by intense
brown staining in the nuclei and cytosol of the treated cells. (C, D) Cells were either untreated (Control) or treated with different agents for indicated
dose and time, and cell lysates were analyzed by Western blotting for levels of CARP-1 and actin proteins as in Methods.
doi:10.1371/journal.pone.0102567.g003
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Figure 4. CFMs activate pro-apoptotic SAPKs in NB cells. (A, B) Indicated cells were either untreated (Control) or treated with respective CFMs
as in figure 2A. Staining of the cells was performed using anti-phospho-p38 antibody as detailed in Methods. Presence of p38 is indicated by intense
brown staining in the nuclei and cytosol of the treated cells. NB cells were either untreated (Control) or treated with indicated CFMs for noted time
and dose, and levels of phosphorylated p38 (noted as p-p38), and total p38 proteins (C, D) or phosphorylated JNK (noted as p-JNK1/2), and total JNK
proteins (E, F) were determined by Western blotting essentially as in figure 2.
doi:10.1371/journal.pone.0102567.g004
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or a 20 mM dose of each of the CFMs however caused a more
pronounced loss of c-Myc expression (Figure 5F). Moreover,
exposure to CFM-4 also resulted in a pronounced loss of cyclin B1
levels in both the NB cells, and a moderate and robust loss of
cyclin B1 occurred in CFM-5-treated SK-N-SH and SK-N-BE(2)
cells, respectively. ADR, on the other hand, was able to target
cyclin B1 in SK-N-SH, but not in SK-N-BE(2) NB cells (Figure 5G,
H). These data collectively suggest that CFM-4 and CFM-5
signaling likely overlap with ADR in down-regulating key cell
proliferation and survival regulating genes to inhibit growth of the
NB cells, and both the compounds are superior in suppressing
MYCN expression when compared with ADR.
NF-kB is a protein complex that regulates transcription of
DNA, and many physiological processes, including cell death and
inflammation. Dysregulation of NF-kB is often encountered in
many human diseases, including cancer [27]. Since IkBa, IkBb,
ABIN-1 and ABIN-2 are known negative regulators of NF-kB
[28–30], and in light of our previous studies demonstrating
diminished expression of these negative regulators of NF-kB
signaling in MPM and MB cells that were exposed to CFM-4
[14,15], here we tested whether treatments of NB cells with CFM-
4 or CFM-5 also reduced expression of IkBa, IkBb, ABIN1 and
ABIN2 proteins. Both SK-N-SH and SK-N-BE(2) NB cells that
were exposed to 10 mM dose of CFM-4 or -5 over a period of 12 h
had reduced levels of IkBa and IkBb proteins when compared
with their untreated controls (Figure 6A, B). Treatments with
either CFMs failed to significantly alter expression of ABIN2 in
SK-N-SH cells while biphasic alteration in ABIN2 expression was
noted in SK-N-BE(2) cell that were treated with either CFMs
(Figure 6A, B). Both the CFMs caused reduced levels of ABIN2 in
SK-N-BE(2) cells over the periods of 1, 3, and 6 h, while
minimally affecting its levels over a 12 h treatment period
(Figure 6B). Likewise a similar biphasic regulation of ABIN1 was
also noted in CFM-treated NB cells. In SK-N-SH cells, treatments
with CFMs over 1, 3, or 6 h periods caused diminished levels of
ABIN1 while a 12 h treatment period elicited a minimal effect on
ABIN1 expression (Figure 6A). On the other hand, in SK-N-BE(2)
cells, CFM treatments over 1 and 3 h periods caused robust
increase in ABIN1 expression, while no such increase was evident
when these cells were treated with either CFM over the 6 or 12 h
periods (Figure 6B). These data indicate that by regulating cellular
levels of ABINs, CFMs likely modulate canonical NF-kB signaling
in a manner dependent on cell-type and treatment durations.
However, a consistent depletion of IkBs by either of the CFMs in
both the NB cells over a 12 h treatment period would argue for
activation of NF-kB signaling by these compounds.
Our previous studies with MB and MPM cells [14,15] together
with our current studies with NB cells suggest that CFMs likely
activate NF-kB signaling. Since CFMs were previously found to
inhibit growth of the HBC cells [10] we next determined whether
and to the extent CFM-4 also activated NF-kB signaling in HBC
cells. MDA-MB-468 HBC cells were either untreated, treated with
CFM-4, CFM-5, or ADR followed by WB analysis of their lysates
for levels of IkBa and IkBb proteins. Consistent with diminished
levels of IkBa and IkBb proteins in the NB cells that were treated
with CFM-4 or CFM-5 compounds, exposure of the HBC cells to
CFM-4, CFM-5, or ADR also caused reduced levels of IkBa and
IkBb proteins (Figure 6E). Additional WB analysis of the cell
lysates derived from the NB and HBC cells that were treated with
CFM compounds failed to reveal loss of expression of the NF-kB
subunits p65 RelA and p50 (not shown). The reduced levels of
IkBa and IkBb proteins without affecting the expression of p65
RelA and p50 proteins would suggest that pleiotropic signaling
induced by CFMs likely involved transcriptional activation of NF-
kB. Since CFMs stimulated CARP-1 expression, and CARP-1 was
required for HBC growth inhibition by CFM-4 [10], we then
determined whether CFM-4 stimulated transcriptional activation
of NF-kB and to the extent CARP-1 was required for transcrip-
tional activation of NF-kB by CFM-4. HBC cells were transfected
with plasmids pTK/Renilla-Luc and NF-kB-TATA-Luc. Twenty-
four hours post-transfections, the cells were either untreated,
treated with recombinant TNFa, ADR, or CFM-4 and the cell
lysates utilized for determination of luciferase activities as detailed
in methods. As shown in figure 6F, each of the agents caused
robust stimulation of NF-kB-TATA-driven luciferase activities
when compared with the luciferase activities noted in the
untreated control cells. Interestingly, knock-down of CARP-1
resulted in significantly reduced NF-kB-TATA-driven luciferase
activities in cells that were treated with TNFa, ADR, or CFM-4
(Figure 6F). Our findings therefore are consistent with the known
transcriptional activation of NF-kB by TNFa, as well as previously
proposed transcriptional activation of NF-kB by ADR. Here we
demonstrate for the first time that CFM-4 treatments also cause
transcriptional activation of NF-kB, and that CARP-1 expression
was necessary for NF-kB activation by TNFa, ADR, or CFM-4. It
however remains to be clarified whether activation of NF-kB
signaling in the presence of CFM-4 or -5 in NB and HBC cells
contributes to apoptosis or serves to promote survival of a small
fraction of cells that may eventually emerge from the stressful
conditions of treatments with CFMs.
CFMs target Inhibitor of Apoptosis Proteins (IAPs) in NB
cells
MicroRNAs (miRNAs; miRs) are small (,22 nucleotide in
length), intracellular, non-coding RNAs that play important roles
in various biological processes. MicroRNAs regulate gene
expression by targeting either 39 or 59-untranslated regions
(UTR) of mRNAs to inhibit translation and thus cause down-
regulation of protein expression [31–33]. Some of the earlier
studies revealed that deregulation of certain miRNAs, often
referred to as onco-miRs, contribute to malignancies including
lung, breast and prostate cancer [34–36]. For example, miR-16
alteration is a key factor in the development of human Chronic
Lymphocytic Leukemia (CLL) [37], whereas a decreased expres-
sion of miR-let7 was reported to be associated with progression of
lung cancer [38]. To further elucidate NB cell growth inhibitory
signaling by CFMs, we investigated whether and to the extent NB
inhibitory effects of CFMs involved altered expression of cellular
miRs. As a first step, we treated SK-N-SH NB, MDA-MB-468
HBC, and H2373 MPM cells with CFM-4 as detailed in methods.
Total RNAs from untreated and treated cells were prepared, and
subjected to a high-through-put miRNA profiling. The data
showing expression of various miRs in control (untreated) and
CFM-4-treated cells are presented as tables S1-S3. A subset of
Figure 5. CFMs suppress expression of oncogenes N and c-myc. (A, B, E) Cells were either untreated (Control), treated with indicated time
and dose of respective CFMs, and followed by staining of cells using anti-N-myc (A, B) or c-myc (E) antibody as detailed in Methods. Presence of N-
myc or c-myc proteins is indicated by intense brown staining in the nuclei of the untreated cells. (C, D, F-H) Cells were either untreated (Control) or
treated with indicated agents for noted time and dose, and cell lysates were analyzed by Western blotting for levels of N-myc (C, D), c-myc (F), or
cyclin B1 (panels G and H) and actin proteins as in Methods.
doi:10.1371/journal.pone.0102567.g005
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Figure 6. CFM-4 activates NF-kB signaling. SK-N-SH (A) and SK-N-BE(2) (B) NB cells were either untreated (Control) or treated with noted CFMs
for indicated dose and time, and cell lysates were analyzed by Western blotting for levels of ABIN1, ABIN2, IkBa, IkBb, a-tubulin and actin proteins as
indicated in Methods. HBC cells were either untreated (Control) or treated with indicated agents for noted time and dose, and levels of IkBa, IkBb (C),
and actin proteins were determined by WB essentially as in figure 2. (D) CFM-4 induces transcriptional activation of NF-kB. Cells were transfected with
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miRs that were regulated by CFM-4 in NB cells is presented in
table 1.
Further analysis of the miR profiling data revealed that miRs
513a-5p, 1290, and 1973 were up regulated significantly in HBC,
NB, and MPM cells that were treated with CFM-4. The miR-
513a-5p was recently found to mediate TNF-a and LPS induced
apoptosis via down-regulation of X-linked inhibitor of apoptosis
protein (XIAP) in endothelial cells [39]. Inhibitor of apoptosis
proteins (IAPs) is family of endogenous inhibitors of caspases and
comprise of XIAP, cIAP1, 2, and survivin proteins. IAPs directly
bind with and interfere with caspases-3, -7 and -9 to block
apoptosis [40,41]. Survivin is involved in mitosis regulation while
its increased expression has been implicated in poor prognosis of
NB [40,41]. We next determined whether growth inhibitory
signaling by CFM-4 involved increased expression of miR-513a-
5p, and consequent down-regulation of XIAP1. For this purpose,
we ablated miR-513a-5p by transfecting anti-miR513a-5p in
MDA-MB-468 HBC cells. Negative control miR as well as miR-
513a-5p mimic were also transfected as additional controls. WB
analysis of the cell lysates revealed that although the transfected
cells overall had reduced levels of XIAP1 when compared to the
untrasfected control, the presence of miR-513a-5p mimic caused
significant reduction in XIAP1 levels in comparison with the
XIAP1 levels in the cells that were transfected with negative
control miR or anti-miR 513a-5p (Figure 7A). Next, the cells were
similarly transfected as in figure 7A, followed by their treatment
with 5 mM CFM-4 for 2 h. Although transfection of miR-513a-5p
mimic caused a moderate but significant loss of cell viability,
NF-kB-TATA-Luc and TK-Renilla-Luc reporter plasmids followed by their treatments with various agents for noted dose and time. Cell lysates were
utilized to determine firefly and Renilla luciferase (internal control) activities as in methods. Columns in the histogram represent relative luciferase
activities from two independent experiments; bars, S.E.
doi:10.1371/journal.pone.0102567.g006
Table 1. List of select miRs that were differentially regulated by CFM-4 in SK-N-SH NB cells.
ProbeID Annotation Average Hy3 SK-N-SH ctrl SK-N-SH CFM-4; 20 mM; 24 h logFC
148085 hsa-miR-3687 9,372 8,512 11,031 2,519
145976 hsa-miR-663b 6,803 5,984 8,353 2,369
169159 hsa-miR-4521 7,015 7,807 5,623 22,183
146165 hsa-miR-1973 9,593 9,000 10,908 1,908
169239 hsa-miR-4732-5p 6,930 6,441 8,243 1,802
46808 hsa-miR-4485 6,581 5,855 7,656 1,801
168568 hsa-miR-1290 7,720 7,295 8,968 1,673
10977 hsa-miR-183-5p 7,104 7,703 6,064 21,639
168765 hsa-miR-4448 5,806 6,378 4,831 21,547
168917 hsa-miR-4511 5,687 5,676 7,206 1,530
168672 hsa-miR-1587 7,375 7,099 8,560 1,461
168640 hsa-miR-4475 8,666 8,578 10,029 1,451
169312 hsa-miR-548an 7,061 7,981 6,565 21,416
147942 hsa-miR-4268 9,770 9,367 10,714 1,347
169034 hsa-miR-642b-5p 10,166 9,732 11,072 1,340
42581 hsa-miR-513a-5p 9,240 9,162 10,475 1,313
168893 hsa-miR-4505 7,743 7,641 8,934 1,293
168572 hsa-miR-4507 6,341 6,067 7,338 1,271
42965 hsa-miR-424-5p 9,422 9,636 8,421 21,216
145768 hsa-miR-665 7,529 6,867 8,067 1,199
169375 hsa-miR-660-3p 10,651 10,265 11,463 1,198
169326 hsa-miR-451b 8,167 8,624 7,429 21,195
169381 hsa-miR-4421 8,968 8,648 9,837 1,189
46258 hsa-miR-1184 7,232 8,143 6,971 21,172
14285 hsa-miR-487b-3p 7,988 8,159 6,990 21,169
169137 hsa-miR-4524b-5p 6,676 7,001 5,860 21,142
17888 hsa-let-7a-3p 6,729 7,286 6,153 21,133
46944 hsa-miR-1297 8,184 8,495 7,380 21,114
11040 hsa-miR-29b-3p 8,902 9,110 8,002 21,108
17377 hsa-miR-600 8,291 8,719 7,624 21,096
Please note that the miRs that were upregulated in CFM-4-treated NB, MPM, and HBC cells are indicated in bold and underlined.
doi:10.1371/journal.pone.0102567.t001
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CFM-4 treatment of miR-513a-5p-transfected cells resulted in
further and significant loss of cell viability (Figure 7B). Consistent
with the profiling data where CFM-4 treatments caused elevated
levels of miR-513a-5p, transfection of miR-513a-5p mimic not
only inhibited cell growth, its presence further enhanced CFM-4
inhibition of MDA-MB-468 cells growth. These data suggest that
CFM-4 suppressed growth of MDA-MB-468 cells in part by up-
regulating miR-513a-5p, which in turn, targets cell survival
regulating XIAP1 protein.
Given that miR-513a-5p targets and down regulates XIAP1
[39], we further clarified whether treatments of NB and HBC cells
with CFM-4 or -5 resulted in loss of XIAP family of proteins. Cells
were untreated, treated with CFM-4, CFM-5, or ADR, and
expression levels of XIAP family of proteins were determined by
WB analysis. As expected, CFM-4 or -5 treatments caused
depletion of XIAP1, cIAP1 and survivin proteins in both the NB
cells (Figure 7C, D). ADR treatments, on the other hand, failed to
diminish expression of XIAP1 and cIAP1 proteins in both the NB
cells albeit survivin expression was reduced in ADR-treated SK-N-
SH cells (Figure 7C, D). Consistent with targeting of XIAP family
of proteins by CFMs in NB cells, treatments with CFM-4 or CFM-
5 also resulted in reduced expression of XIAP1 and cIAP1 proteins
in HBC cells (Figure 7E). ADR treatments although abolished
XIAP1 expression but failed to diminish cIAP levels in HBC cells
(Figure 7E). Our miR expression analysis together with WB data
strongly suggests that CFMs inhibit NB and HBC cell growth in
part by targeting XIAP family of proteins.
CFMs suppress NB cell migration, colony formation and
matrix invasion
Further, we determined whether CFMs inhibit biological
properties of NB cells such as migration, colony formation and
invasion, and the molecular mechanisms involved. Exposure of
CFM-1, -4, or -5 caused significant reduction in size and number
of colonies formed by SK-N-SH and SK-N-BE(2) cells in soft agar
as well as prevented SK-N-SH cells from growing in the areas of
wound created by a scratch when compared with their untreated
counterparts (Figure 8A, B). Our earlier studies have revealed that
CFMs caused down regulation of various matrix metalloprotei-
nases (MMPs) in different cancer cell types [14,15]. Since MMPs
and their cognate inhibitors, often referred to as tissue inhibitors of
metalloproteinases (TIMPs) are known for their roles in the
processes of tissue remodeling, cancer cell invasion and metastasis,
and given that CFMs inhibit NB cell migration and colony
formation, we next investigated whether CFMs also modulated
activities of MMPs and/or TIMPs in NB cells. To test this
possibility, we performed antibody-based array analysis to
determine the activation of various MMPs and TIMPs in NB
cells following their treatments with CFM-4 or -5 as detailed in
methods. Although, both CFM-4 and CFM-5 attenuated activities
of MMP-1, -8, -9 in MPM cells [14], and MMP-1, -2, -9, -10 in
MB cells [15], a moderate but significant loss of only MMP-9
activity was noted in SK-N-SH NB cells that were treated with
CFM-4 or CFM-5 (Figure 8C). In addition to MMP-9 inhibition,
we also observed moderate albeit significant activation of TIMP2
in SK-N-SH cells that were treated with CFM-4 or CFM-5
(Figure 8C). CFM-5 but not CFM-4 also caused robust activation
of TIMP1 in NB cells (Figure 8C). Our WB analysis further
revealed an appreciable increase in TIMP2 levels in SK-N-SH
cells when exposed to CFM-4 or CFM-5 when compared with
their untreated counterpart (Figure 8D). We next examined
whether attenuation of MMP-9 and stimulation of TIMP-1 & -2
activities in CFM-treated SK-N-SH cells interfered with invasive
properties of NB cells. To test this possibility, we determined the
extent to which CFMs blocked the ability of NB cells to invade
through matrigel-coated membranes as detailed in methods. As
expected, treatments of NB cells with CFM-4 or CFM-5 caused
significantly reduced number of cells that were able to invade
through the matigel-coated membranes (Figure 8E). Of note here
is that although CFM-1 treatments elicited a moderate loss of
viability of different NB cells (see figure 1), it was nonetheless
effective in blocking NB cell migration, growth in soft agar, and
invasion across the matrigel-coated membranes (Figure 8A, B, E).
These data together with our earlier studies with MPM and MB
models strongly support our hypothesis that CFMs, in particular
CFM-4, interfere with NB cell invasion and metastasis signaling in
part by targeting MMP-9 activation.
Discussion
Our previous studies revealed that CFMs are a novel class of
compounds that suppress growth of diverse types of cancer cells in
part by inducing apoptosis [10,14,15]. Here, we highlighted the
anti-NB properties of CFMs. CFMs, particularly CFM-4, -5,
inhibited NB cell growth by causing G2M cell cycle arrest and loss
of mitotic cyclin B1. CFMs stimulated CARP-1 expression and
activation of stress-activated p38/JNK and NF-kB signaling
pathways. Additionally, our present study revealed that CFMs
induced growth inhibition of NB cells that involved down
regulation of oncogenic MYCN and c-Myc proteins, while causing
up-regulation of miR-513a-5p, which targets and abrogates XIAP-
1 expression. In addition to XIAP-1, CFMs also induced loss of
cell survival-associated c-IAP1 and survivin proteins.
Previous evidence have shown that MYCN amplification is one
of the critical aspects in tumor progression and poor prognosis in
NB, and MYCN is often considered an attractive target for
therapeutic intervention strategies in this malignancy [42–45]. In
addition to anti-proliferative properties, CFMs induced loss of
MYCN in both SK-N-SH and SK-N-BE(2) cells that have single
copy of MYCN and amplification of MYCN, respectively. Since
CFMs stimulate CARP-1 expression, and in light of our previous
studies demonstrating increased CARP-1-dependent apoptosis in
HBC cells expressing reduced levels of c-Myc [6], it is likely that
CARP-1 is involved in targeting of MYCN by CFMs in NB cells.
Moreover, our current studies revealed that CFMs also targeted c-
Myc expression in SK-N-SH NB cells, and the facts that both
Figure 7. CFM-4 inhibits cell growth in part by inducing a novel miR-513a-5p and suppressing Survivin family of proteins. (A) MDA-
MB-468 HBC cells were either untransfected (Control) or transfected with various miRs as noted. Levels of XIAP1 and actin proteins were determined
by Western blotting. The signals for the XIAP1 and actin proteins were quantified by densitometry, and the numbers below XIAP1 blot indicate levels
of XIAP1 protein in each lane following normalization of the signals with actin levels. For the sake of comparison, the signal intensity for XIAP1 in
control (Untreated) lane was assigned an arbitrary value of 1. (B) HBC cells were either untransfected or transfected with various miRs as in A, and
subsequently treated with vehicle (DMSO) or indicated time and dose of CFM-4. Determination of viable/live cells was carried out by MTT assay. The
data in the histogram represents means of two independent experiments; bars, S.E. *, @, and #, p =,0.03 relative to respective untreated controls.
NB or HBC cells were either untreated (Control) or treated with indicated agents for noted time and dose, and levels of XIAP1, cIAP1, survivin, a-
tubulin, and actin proteins (C, E) were determined by Western blotting essentially as in figure 2.
doi:10.1371/journal.pone.0102567.g007
CFMs Are Novel Inhibitors of Neuroblastoma
PLOS ONE | www.plosone.org 13 July 2014 | Volume 9 | Issue 7 | e102567
CFMs Are Novel Inhibitors of Neuroblastoma
PLOS ONE | www.plosone.org 14 July 2014 | Volume 9 | Issue 7 | e102567
MYCN and c-Myc belong to Myc transcription family and are
well known for their roles in tumorigenesis, our studies highlight
ability of CFMs to target Myc family of onco-proteins to transduce
their growth inhibitory effects.
We have previously noted a biphasic regulation of NF-kB
signaling in MB and MPM cells that were treated with CFM-4
[14,15]. Consistent with these observations, our current studies
revealed that the CFMs also caused a biphasic regulation of NF-
kB in NB cells. Although, the CFMs seemed to generally inhibit
the canonical pathway of NF-kB activation as evidenced by
increased expression of ABINs, expression of IkBa and IkBb
proteins were nonetheless down-regulated in CFM-treated NB
cells. This loss of IkBs in CFM-treated cells would be expected to
result in nuclear translocation and activation of transcriptional
signaling by NF-kB [46]. Indeed our data not only demonstrate
that CFM-4 exposure caused a robust transcriptional activation of
NF-kB in HBC cells, we show for the first time that CARP-1/
CCAR1 expression was necessary for transcriptional activation of
NF-kB by TNF-a, ADR, or CFM-4 compounds. Whether and to
the extent the NF-kB activation by these agents promoted
transcription of cell survival and proliferation regulating genes or
was involved in stimulation of apoptosis is not known albeit a
number of recent studies have proposed pro-apoptotic functions of
NF-kB signaling [47–49]. Of note is the fact that although NF-kB
regulates transcription of many survivin family proteins including
XIAP1, CFMs nonetheless promoted loss of these proteins in NB
and HBC cells. It is unclear whether the diminished expression of
the survivin family of proteins in the presence of CFMs involves
NF-kB-dependent transcriptional mechanisms or the activation of
NF-kB occurs to support survival of the cells that are able to
eventually overcome the stress and damaging effects of CFMs.
Micro RNAs (miRNAs) are endogenous, single stranded, small
non-coding RNA molecules that regulate gene expression at
transcriptional and post-transcriptional levels, and are implicated
in various biological processes [50–52]. Recent studies demon-
strated that deregulation of miRNAs contributed to various
malignancies. For example, miR15 and miR16 deletion was
found in more than 65% of Chronic Lymphocytic Leukemia
(CLL) [33,52]. Consistent with a previous study demonstrating
XIAP targeting by miR-513a-5p during TNF-a and LPS-induced
apoptosis signaling in endothelial cells [39], our miRNA profiling
studies revealed upregulation of miR-513a-5p in CFM-4-treated
NB, HBC, and MPM cells. Although, treatments with either
CFM-4 or -5 resulted in diminished expression of XIAP1 in NB
and HBC cells, CFM-4-treatment of miR-513a-5p mimic
expressing HBC cells further enhanced their growth inhibition
when compared with their vehicle-treated counterparts. The
expression of anti-miR-513a-5p on the other hand interfered with
HBC cell growth inhibition by CFM-4, suggesting that miR-513a-
5p signaling was likely involved in CFM-4 targeting of XIAP and
consequent growth inhibition of HBC and NB cells. Whether
similar post-transcriptional targeting of other survivin family of
proteins by additional miRs occurs as well as NF-kB signaling
stimulates transcription of survivin family of proteins in cells
exposed to CFMs, and to the extent the post transcriptional
targeting of such mRNAs by miRs is greater than their
transcriptional up-regulation by NF-kB to result in overall
decreased expression of the survivin family of proteins in the
presence of CFMs remain to be clarified.
In addition to miR-513a-5p, the miR profiling also revealed
miRs 1290 and 1973 that were also elevated in NB, HBC and
MPM cells that were treated with CFM-4 (Table 1). Although a
survey of the miR database indicated an array of putative mRNA
targets of these miRs, whether and to the extent the miR-1973
functions as a tumor suppressor or onco-mir remain to be
determined. In regard to miR-1290, recent reports have revealed
that its expression and its potential targets were associated with
characteristics of estrogen receptor (ER)a-positive breast cancers
while its elevated serum levels were found to be associated with
patients with low-stage pancreatic cancers [53,54]. Interestingly,
expression of miR-1290 was also found to favor mitotic exit and
differentiation processes of human neuronal progenitors [55]. In
this study, upregulation of miR-1290 was noted in SH-SY5Y NB
cells that were induced to differentiate into neurons, while ectopic
expression of miR-1290 in undifferentiated SH-SY5Y NB cells
resulted in a higher number of cells in the G0/G1 phase of cell
cycle. Expression of miR-1290 in the undifferentiated neuronal
progenitor cells resulted in increase in cyclin-dependent kinase
inhibitor (CDKI) p27kip1 and a decrease in the levels of
proliferating cell nuclear antigen (PCNA). The fact that miR-
1290 levels were elevated in ERa-negative MDA-MB-468 HBC
cells that were treated with CFM-4 (Table 1) and CFM-4 exposure
also resulted in inhibition of ERa-positive MCF-7 cells [10],
further studies will be necessary to clarify whether and to the
extent elevated expression of miR-1290 contributes to growth
inhibition of the NB and HBC cells in the presence of CFM-4.
In conclusion, the studies presented here demonstrate that
CFMs suppressed growth of NB cells. CFMs targeted cell survival
and growth by down-regulating oncogenes of the Myc family, as
well as a number of survivin family of proteins. The robust
activation of pro-apoptotic p38 and JNK SAPKs likely served to
potentiate NB inhibitory effects of CFMs. CFMs also inhibited
MMP-9 activation while stimulating expression of MMP inhibitor
TIMP2. MMP-9 was induced in ERK dependent signaling to
promote invasion in colorectal cancer [56], and TIMP2 was noted
as a transcriptional signature in inhibiting tumorigenesis and
metastasis of lung cancer cells [57]. Thus attenuation of MMP-9
together with activation of TIMP2 likely contributed to inhibition
of biological properties of migration and invasion of NB cells in the
presence of CFMs.
Figure 8. CFMs inhibit NB Cell Growth in Soft Agar, invasion and MMP activities. NB cells were either untreated (Control) or treated with
indicated CFMs as in methods, and were subjected to the soft-agar assay (A) or scratch assays (indicated as wound healing assay; panel B). The
number if colonies of cells in panel A or cells growth in the scratch assay were recorded by photography as described in Methods. Representative
photomicrographs of untreated and CFM-treated NB cells are shown. (C) The SK-N-SH cells were either untreated [Control (DMSO)] or treated with
CFM-4 or CFM-5 for noted dose and time. Cell lysates were analyzed for activities of various MMPs and TIMPs as detailed in Methods. The data in the
histogram represents means of the activities of the noted MMPs and TIMPs from two independent experiments; bars, S.E. (*, #, and @, p=,0.05
relative to respective MMP and TIMP activities in Control cells). (D) The SK-N-SH were either untreated (Control) or treated with indicated time and
dose of respective CFMs. Levels of TIMP2 and a-tubulin proteins were determined by Western blotting essentially as in figure 2. (E) NB cells were
separately seeded in chambers with matrigel-coated membranes, and treated with buffer Control (DMSO) or with 7 mM dose of respective CFMs as
noted in Methods. Live cells migrating across the matrigel-coated membranes were dissociated, and quantitated by an MTT-based assay. The
columns in histogram represent MTT OD of the CFM-treated NB cells relative to untreated controls. (*#, $, %, and &, p =,0.02 relative to buffer-
treated, Control cells.
doi:10.1371/journal.pone.0102567.g008
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Supporting Information
Table S1 List of CFM-4-regulated miRs in SK-N-SH NB cells.
(XLSX)
Table S2 List of CFM-4-regulated miRs in H2373 MPM cells.
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